Market Overview

Benzinga's Top Pre-Market Losers

Related FOLD
Earnings Scheduled For March 3, 2014
UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious View of Migalastat Monotherapy
Related GSK
Glaxo's Tanzeum Approved in the U.S. - Analyst Blog
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Amgen, GSK End Marketing Pact for Osteoporosis Drug (Fox Business)

Amicus Therapeutics (NASDAQ: FOLD) shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc (NYSE: GSK) today announced the 6-month primary treatment period results from the first Phase 3 global registration study.

Allscripts Healthcare Solutions (NASDAQ: MDRX) shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO.

Accenture plc (NYSE: ACN) dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion.

Bed Bath & Beyond (NASDAQ: BBBY) dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Most Popular

Related Articles (BBBY + ACN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free